Adicet Bio, Inc.
ACET
Rank in Stocks
#25142
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic... Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The companyโs strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Share Price
$2.99
Last synced: 2026-11-09
Market Cap
$27.99M
Change (1 day)
-1.97%
Change (1 year)
-71.08%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Adicet Bio, Inc. (ACET)
Category
Healthcare
Operating Margin for Adicet Bio, Inc. (ACET)
Operating Margin as of November 2026 TTM: 0.00%
According to Adicet Bio, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Adicet Bio, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -290.32% | -54.02% |
| 2021 | -631.38% | 188.42% |
| 2020 | -218.91% | -93.06% |
| 2019 | -3,154.57% | 1,624.66% |
| 2018 | -182.91% | 5,311.54% |
| 2017 | -3.38% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | 8.68% | 25.98% |
| 2014 | 6.89% | 0.00% |
| 2013 | 6.89% | 20.67% |
| 2012 | 5.71% | 42.39% |
| 2011 | 4.01% | 47.43% |
| 2010 | 2.72% | -26.29% |
| 2009 | 3.69% | -37.88% |
| 2008 | 5.94% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Adicet Bio, Inc.'s operating margin
What was Adicet Bio, Inc.'s operating margin in 2025?
In 2025, Adicet Bio, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Adicet Bio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Adicet Bio, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-631.38%).
How does Adicet Bio, Inc.'s operating margin compare with similar companies?
Adicet Bio, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.